Abstract
Injectable somatostatin receptor ligands (iSRLs) are used to treat acromegaly. However, injection site reactions (ISRs) are common and impact patient activities of daily living and quality of life (QOL).1-3 Recently, oral octreotide capsules (OOC; MYCAPSSA®) were approved in the United States as a new treatment option for adult patients with acromegaly previously responding to iSRLs (octreotide or lanreotide). MPOWERED is a phase 3 trial assessing maintenance of response to OOC compared to iSRLs in patients with acromegaly. Here we report ISR-related data from patients receiving iSRLs in the randomized controlled treatment (RCT) phase of the MPOWERED trial.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
